Sandoz wades into Humira biosimilars

Share this article:

Novartis's generics arm, Sandoz, is taking on AbbVie's multi-indication medication Humira. The company announced Wednesday that it had kicked off a Phase III trial of an adalimumab biosimilar. It said the trial's goal is to “demonstrate efficacy, similarity and immunogenicity of the Sandoz product versus Humira” in moderate-to-severe plaque psoriasis patients.

The division's head of biopharmaceuticals and oncology injectables, Ameet Mallik, said in a statement that the Humira biosimilar will be “a key building block in our growing immunology portfolio” and that the company has Phase III trials in effect for biologics including Amgen's Enbrel and Roche's Rituxan.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.